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Abstract 
Background and aims: Several studies describe an association between vitamin D and 
glucose metabolism, however data are ambiguous. We aimed to study the relationship 
between serum levels of 25(OH) vitamin D and insulin action in subjects with type 2 diabetes 
and hypovitaminosis D.  
Methods: Twenty-six subjects with type 2 diabetes and hypovitaminosis D, recruited from 
the DIVINE study (Diabetes Intervention Trial with Vitamin D in Subjects of Sub-Indian and 
Nordic Ethnicity), were included in the present analysis. Insulin action was measured as 
homeostasis model assessment of insulin resistance (HOMAIR) and with the hyperinsulinemic 
euglycemic glucose clamp method.  
Results: Subjects had a mean age of 57 years, a mean BMI of 31,1 kg/m2 and a median S-
25(OH) vitamin D of 39 nmol/l. S -25(OH) vitamin D did not correlate with measures of 
insulin action and was not significantly different between subjects of Nordic and South-Asian 
ethnicity.  
Conclusions: S-25(OH) vitamin D did not correlate significantly with any measures of insulin 
action in subjects with hypovitaminosis D and type 2 diabetes. Possibly, a study including 
more subjects can detect such a relationship.  
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1 Introduction 
1.1 Type 2 diabetes 
Type 2 diabetes is an increasing public health problem worldwide (1), and type 2 diabetes 
constitutes 85% to 95% of all diabetes in high-income countries and probably an even higher 
percentage in low- and middle income countries (2). It is estimated that 285 million people 
have diabetes in 2010. The prevalence of diabetes is estimated to almost double from year 
2000 till 2030 in Norway and more than double in for example Pakistan, India and 
Bangladesh (3). 
The complications associated with diabetes places a great burden on the individual and also 
on the society. Prolonged hyperglycemia is associated with changes in both the micro- and 
macrovasculature and causes damage in the eye, kidney and nerve tissue as well as 
accelerating atherosclerosis in larger arteries. Diabetes is the most common cause of 
blindness among subjects in working age and among the most common single causes of end 
stage renal failure worldwide. Diabetes is also the most common cause of non-traumatic 
lower limb amputation, as a consequence of neuropathy. Furthermore, people with diabetes 
have a significantly increased mortality from ischemic heart disease and stroke compared to 
an age- and sex-matched non-diabetic population (4). The total amount of deaths due to 
diabetes worldwide in 2010 is estimated to almost four million, or in other words, it is 
responsible for 6,8% of deaths in subjects between 20-79 years (5).  
Today we know that type 2 diabetes is characterized by a variable degree of insulin 
resistance and relative insulin deficiency caused by 
hereditary disposition in combination with risk 
factors, such as overweight and physical inactivity. 
When insulin secretion no longer can keep blood 
glucose levels normal, diabetes results. The high 
blood glucose levels results from a combination of 
increased glucose production by the liver and 
delayed uptake of glucose in peripheral tissue, 
predominantly skeletal muscle (7). Inflammation is 
probably part of the pathogenesis of type 2 
Textbox 1. 
A link between diabetes and the pancreas 
was established in the 19
th
 century when 
pancreas from dogs were removed and 
clinical signs characteristic of diabetes 
mellitus were observed; thirst, polyuria 
and wasting associated with glucosuria 
and hyperglycemia. Insulin was discovered 
1921 at the University of Toronto and it 
was shown that extracts from the 
pancreas of dogs lowered the blood 
glucose concentrations in 
pancreatectomised dogs. (6) 
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diabetes as well (8).   
As type 2 diabetes is a major health problem large efforts are made to understand its 
pathophysiology to be able to develop effective prevention and treatment of the disease. 
Recently, vitamin D has been introduced as a possible important factor. 
1.2 Vitamin D  
Vitamin D is derived from sterols in the skin when exposed to the ultraviolet rays in sunlight 
(9). It can also be obtained from food; fatty fish, eggs or vitamin D fortified foods (9;10). 
Vitamin D is hydroxylated first in the liver and then in the kidneys, to result in its active form, 
1,25(OH)2D3  (figure 1). This active form of vitamin D promotes intestinal absorption of 
calcium and phosphate, decreases renal excretion of calcium and phosphate and promotes 
bone calcification - thereby contributing to the feedback regulation of calcium and 
phosphate in extracellular fluid. Lack of vitamin D, leading to calcium or phosphate 
deficiency in extracellular fluid, 
therefore can cause rickets in 
children and osteomalacia in 
adults (9).  
Aside from effects on bone 
metabolism, vitamin D may also 
have other important 
physiological effects. Many 
tissues, including the pancreas, 
expresses vitamin D receptors 
and also have the ability to 
convert 25(OH)D to its active 
form 1,25(OH)2D by the 
expression of 25-hydroxyvitamin 
D-1-α-hydroxylase (11). This active form acts at the cell nucleus and at the cell membrane in 
over 30 tissues and organs. It has been increasingly documented that vitamin D has 
endocrine effects in the kidney and intestine, autocrine effects on cell differentiation, 
Figure 1. Overview of vitamin D metabolism showing steps 
of hydroxylation. Illustration: R&D systems, 
www.rndsystems.com 
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proliferation and immune modulation and cell membrane effects in intestinal absorption of 
calcium. 
Vitamin D deficiency is associated with increased cortical bone loss, increased bone turnover 
and increased levels of parathyroid hormone, predisposing to osteoporosis. Associations has 
also been made between low serum levels of 25(OH) vitamin D and cardiovascular disease, 
the development of autoimmune disease and certain cancers (colon- prostate- and breast 
cancers) (10). Epidemiological studies indicate that serum levels below 20 ng/ml (50 nmol/l)* 
25(OH) vitamin D increases the risk of incidence of these cancer forms with 30-50% and also 
increases the mortality. Vitamin D-deficiency causes muscle weakness and adequate 
supplementation has been shown to reduce falls. A link to increased risk of depression and 
schizophrenia has also been made (12).  
There is no absolute consensus for what a normal range of  S-25(OH) vitamin D is but most 
experts now agree that deficiency is defined as levels < 20 ng/ml (50 nmol/l)* and that 
insufficiency can be considered as levels between 21-29 ng/ml (52-72 nmol/l)*. It is 
recognized that 30-50% of both the European and US population are vitamin D deficient or 
insufficient (13).  
1.3 Vitamin D and glucose metabolism 
Observational studies have shown an inverse association between S-25(OH) vitamin D status 
and the prevalence and/or incidence of diabetes, metabolic syndrome, hyperglycemia and 
insulin resistance (14-17). Pittas et al. found that a higher intake of vitamin D among U.S. 
female nurses, especially in form of supplements, was associated with a lower risk of 
diabetes (18). A seasonal variation has been reported, with a higher incidence of type 2 
diabetes and poorer glycemic control in winter months and early spring, when levels of S-
25(OH) vitamin D tend to be lower (19). 
There is evidence that vitamin D plays a role in insulin secretion in animals, but results from 
studies in man are inconclusive. Likewise have studies regarding the effect of S- 25(OH) 
vitamin D on insulin sensitivity shown ambiguous results (20). There is a need for adequately 
powered randomized controlled trials exploring if supplementation to adequate serum levels 
                                                          
* Conversion factor to SI units: 2,496 
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of vitamin D actually improves glycemic control in already manifest disease and if 
supplementation is safe, acceptable and efficient enough to implement into clinical practice 
1.4 Aim 
The aim of this project work is to investigate the relationship between S-25(OH) vitamin D 
concentrations and insulin sensitivity in subjects with type 2 diabetes. To explore this, I used 
baseline data from the first 26 subjects included in an ongoing intervention study at the 
Department of Endocrinology, Oslo University Hospital, Aker. The DIVINE-study (Diabetes 
Intervention Trial with Vitamin D in Subjects of Sub-Indian and Nordic Ethnicity) is a 
randomized controlled trial with the primary objective to compare the change in insulin 
sensitivity, measured with euglycemic hyperinsulinemic clamp, in patients with 
hypovitaminosis D and type 2 diabetes treated for 26 weeks with high dose vitamin D or 
placebo.  
2 Material and methods 
2.1 Subjects 
Baseline data from the first twenty-six subjects included in the DIVINE study was used in the 
present project.  All subjects had type 2 diabetes, S-25(OH) vitamin D ≤ 50 nmol/l, were of 
Nordic or South-Asian ethnicity, above 18 years of age and able to communicate in 
Norwegian.  Among the study exclusion criteria were untreated high blood pressure, liver or 
kidney disease, malignancy, hypercalcemia, a history of kidney stone disease, a history of 
cardiovascular event during the last six months, anemia or BMI >45kg/m². Women in 
reproductive age had to use adequate contraception. Subjects were recruited from 
advertisements, local general practitioners and the outpatient clinic at the Department of 
Endocrinology at Oslo University Hospital. All subjects had given their informed consent to 
participate before any study related procedures. The study was approved by the regional 
ethics committee and the Norwegian Medical Agency.  
2.2   Study procedures  
DIVINE is a randomized, double blind, placebo controlled trial with the primary objective to 
compare the change from baseline insulin sensitivity, measured with euglycemic 
hyperinsulinemic clamp, in subjects with hypovitaminosis D and type 2 diabetes treated for 
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26 weeks with vitamin D or placebo. The main hypothesis is that vitamin D supplementation 
in patients with type 2 diabetes will improve insulin sensitivity and glucose metabolism.                                                                                                   
 At the screening visit S-25(OH) vitamin D, S-ionized calcium and S-PTH were measured and 
suitability according to inclusion and exclusion criteria was checked. After this subjects were 
enrolled into a 4 weeks lead in phase with the purpose to stabilize their diabetes treatment. 
At this time all patients were also give calcium supplementation 250 mg bid to be continued 
throughout the study period of 30 weeks (4 weeks lead in phase and 26 weeks of double –
blind treatment). At visit 3 subjects were completely physically examined and measured 
body composition of, using DEXA. Height and weight were measured in light clothing, 
without shoes. At visit 4 a combined IVGTT and euglycemic hyperinsulinemic clamp with 
measurement of hepatic glucose production, using the stable isotope dilution method, was 
performed to measure insulin sensitivity and secretion at baseline. Subjects were informed 
to meet in the fasting state. No food, but water, was allowed after midnight the night 
before. Oral antihyperglycemic agents were withdrawn 48 hours and insulin 12 hours prior 
to the procedure and subject avoided strenuous physical exercise and alcohol the day before 
the investigation. 
2.3 Biochemical measurements 
S-25(OH) vitamin D is a valid marker of vitamin D status (13) and was measured at the 
Hormone Laboratory using the DiaSorin 25(OH) vitamin D radio immunoassay. The Hormone 
laboratory reports an intra-assay coefficient of variance of 6% for this analyze. The reference 
value for S-25(OH) vitamin D according to the Hormone Laboratory is 37-131 nmol/l (21), 
and according to Fürst 50-150 nmol/l (22). Glucose was measured locally with an YSI 2300 
(Yellow Springs Instruments, Ohio, USA) using a glucose oxidase method. S-insulin 
concentrations were determined using a human immunometric assay kit (AutoDELFIA 
Insulin, Perkin Elmer Life Sciences, Wallac Oy, Turku, Finland) on a 1235 automatic 
immunoassay system (Wallac 1235 AutoDELFIA, Wallac Oy, Turku, Finland). P-total 
cholesterol, P-HDL-cholesterol and P-triglycerides were determined with enzymatic 
colorimetric kits (Roche Diagnostics, Mannheim, Germany). P-LDL was calculated using the 
Friedwald formula. S-Ionized calcium was measured using Rapidlab 348 pH/Blood Gas 
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Analyzer and PTH was analyzed in serum with a non-competetive immunoluminometric 
assay (Immulite 2500 from Siemens Healthcare Diagnostics, Los Angeles, CA, USA). 
2.4 Measurement of insulin sensitivity 
2.4.1 Homeostasis model assessment  of insulin resistance -HOMAIR 
Homeostasis model assessment of insulin resistance derives from a mathematical model of 
the glucose-insulin homeostatic system. This model can be used to calculate an index of 
insulin resistance in the fasting state from fasting P-glucose and fasting S-insulin (23). The 
HOMA2 calculator (http://www.dtu.ox.ac.uk/homacalculator/index.php) was used here and 
the fasting samples of P-glucose (mmol/l) and S-insulin (pmol/l) were inserted. This 
calculator does not accept values of insulin above 400 pmol/l. For two of the subjects 
measured S-insulin exceeded this value and for the purpose of calculating HOMAIR they were 
set to 400 pmol/l.  
2.4.2 IVGTT 
A glucose bolus of 0,3g/kg body weight was given over one minute and then glucose-, 
insulin-, and c-peptide concentrations were measured at 0,2,4,6,8,10, 15 and 30 minutes. 
Insulin secretion in response to hyperglycemia can then be studied, as the purpose of the 
IVGTT is in DIVINE . An IVGTT also gives an opportunity to estimate the insulin sensitivity. 
The glucose concentration reaches a peak value and then starts to decline. Insulin, released 
in response to the increased glucose concentration, accelerates the decline – how much 
depends on the insulin level and its action. With the minimal model, a mathematical 
representation of the glucose-insulin relationship, the insulin sensitivity index (Si) can be 
calculated (25). This index will not be used here. 
2.4.3  Hyperinsulinemic euglycemic clamp  
The glucose clamp technique in its euglycemic version is generally accepted as the gold 
standard for measurement of insulin action (25). Insulin (Actrapid, NovoNordisk, Denmark) 
was infused to create a stable level of hyperinsulinemia. First a priming dose was given, 
calculated from the patient’s pre-clamp plasma glucose (those with a P-glucose above 13 
mmol/l when the clamp started were given an extra bolus of insulin) then insulin was infused 
at a constant rate of 80 mU/m2/min. Since a glucose bolus of 0,3g/kg body weight was given 
in the preceding IVGTT  the P-glucose was monitored by measuring P-glucose every five 
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minutes. When P-glucose had declined to between 6,0-5,5 mmol/l one started a variable 
glucose infusion (glucose 200 mg/ml, enriched with the tracer - 8mg/g glucose ) with the aim 
to keep P-glucose as close to 5 mmol/l as possible. This was done by measuring P-glucose 
every five minutes and adjusting the glucose infusion rate empirically according to the result. 
For two of the subjects (one Nordic, one South-Asian) one was not able to reduce the P-
glucose to 5,5-6,0 mmol/l, suggesting they were highly insulin resistant, and calculations of 
glucose infusion rate and insulin sensitivity index for those were therefore not done. The 
total clamp duration was set to 150 minutes and the glucose infusion rate was calculated 
from the last 30 minutes of stable euglycemia. S-insulin, P-glucose and glucose tracer were 
measured 30, 20 and 10 minutes before the end and at the end of the clamp. The  glucose 
infusion rate (GIR, mmol/m2/min) required to maintain constant euglycemia during the 
period of constant hyperinsulinemia provides a measure for the net effect of insulin on 
whole body glucose metabolism (26). After the infusions were switched of the subjects were 
asked to void and the urine volume was measured and urine samples were stored. Glucose 
lost via the urine was not taken into account in the present analyze of data.  
Technically there are three major requirements to perform a glucose clamp. Two 
intravenous lines, for example one in each antecubital vein, must be kept patent throughout 
the study. One for infusions of glucose and insulin and one for sampling. The arm where 
samples were taken from was heated with a heating sleeve to 37°C to arterialize the blood 
taken for samples (25). The heating induces vasodilatation, arteriovenous anastomoses are 
opened, which reduces the blood transit time and thus also the arterio-venous difference in 
glucose concentration that would otherwise lead to a systematic underestimation of the 
actual P-glucose. Glucose would be over-infused and insulin sensitivity overestimated. The 
difference in arterial glucose concentration between individuals is also proportional to the 
insulin sensitivity and thus, theoretically, would lead to a greater overestimation in more 
insulin sensitive individuals (26). Second, pumps for infusion of glucose and insulin must be 
well-calibrated and must have sufficiently fine gears for one to adjust the glucose infusion 
rate to keep P-glucose as stable as possible. Third, samples for P-glucose must be analyzed 
quickly in order to be able to make necessary adjustments of the glucose infusion rate. 
Glucose must then, after the adjustment of the glucose infusion rate, again come to 
equilibrium with the extravascular, extracellular glucose compartment, before next sample 
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of P-glucose is drawn, not to overestimate the effect of the new glucose infusion rate 
(25;26). 
Clamp data was standardized for the purpose of comparison. Insulin was administered per 
unit of body surface area to avoid administering to much insulin in obese individuals. Since 
muscle tissue is the principle site of glucose uptake, glucose infusion rate is best normalized 
by the fat-free mass, i.e. lean body mass. To account for differences in the clamp insulin 
levels one can correct for the clamp-insulin concentration (25). 
An index of insulin sensitivity (ISI) can thus be expressed as GIRffm/I, where GIRffm is the 
glucose infusion rate normalized for fat free mass and I is the mean insulin concentration 
during the steady state period of the clamp. As dividing GIRffm with S-insulin gives a very 
small number, it was multiplied with 1000 to give a more suitable number.  
2.4.4  The stable isotope dilution technique 
The purpose of this method is to measure the endogen glucose production, where of the 
major part is of  hepatic origin. The glucose utilized by the body during constant P-glucose 
equals the sum of glucose infused and endogen glucose produced. Normally an insulin 
infusion rate of 80 mU/min/m2 would almost totally suppress the hepatic glucose production 
(HGP) but it has been demonstrated that insulin is less effective in suppressing HGP in 
subjects with type 2 diabetes (27). Since all the subjects in this material have diabetes one 
can not assume that HGP equals zero and therefore must measure it not to underestimate 
the glucose-utilization. The HGP rate also offers an idea of hepatic resistance to the 
suppressive actions of insulin, a higher rate of HGP indicating a higher degree of hepatic 
insulin resistance.  
 With the infusion of a tracer, in this case deuterium labeled glucose ([6,6-2H2 ]glucose), HGP 
can be calculated. A tracer behaves like the tracee i.e. glucose. In [6,6-2H2 ]glucose two 
hydrogen atoms on glucose is replaced by deuterium (hydrogen with two neutrons instead 
of one) and can therefore be differentiated from glucose by its higher molecular weight. 
When the amount of infused tracer and glucose into an estimated volume  is known, one can 
calculate what the theoretical concentration of the tracer would be if infused glucose was 
the only source of P-glucose. If glucose in addition is endogenously produced, the measured 
tracer-concentration will be lower than it was calculated to be. The difference between the 
12 
 
calculated and the measured tracer-concentration gives the amount of endogenously 
produced glucose. Under non-steady-state conditions, as during the infusion of insulin and 
glucose, HGP is calculated using formulas such as Steel´s equation (28). However, in this 
analyze of data, tracer-concentrations were not available and HGP has therefore not been 
calculated.  
2.5 Statistical analyses 
Normally distributed data are presented with mean and standard deviation and data not 
normally distributed are presented with median, 25th and 75th percentiles (interquartile 
range). Two- sample t-test was performed in Excel 2007 to compare subgroups for data 
considered to be normally distributed. For non-parametric data, independent samples 
Mann-Whitney U tests were used to compare groups. For testing significance of 
crosstabulated variables Chi-square test was applied. The tests were performed two sided 
and a p-value ≤ 0,05 was considered significant. In addition correlations were calculated 
using Spearman’s rank correlation coefficient. The effect of levels of S-25(OH) vitamin D was 
also explore by comparing glucose parameters in two groups; one with S-25(OH) vitamin D 
above/equal to 40 nmol/l and one with S-25(OH) vitamin D below 40 nmol/l. We also 
explored the effects of ethnicity by comparing Nordic to South-Asian subjects. Non-
parametric tests, correlations, chi-square, histograms and plots were done in PASW Statistics 
18. For two of the Nordic subjects HbA1c, P-cholesterol, P-HDL, P-triglycerides and P-glucose 
are missing. P-LDL is missing in three Nordic subjects. S-ionized calcium is missing in one 
Nordic subject.  
3 Results 
A total of 26 subjects were included in this analysis. Two thirds of subjects were men. In the 
South-Asian group six were from Pakistan, three from Sri Lanka and one from India. Six 
included subjects were treated with diet only and twenty received antihyperglycemic 
medication (nine were on insulin, with or without oral antihyperglycemic agents, and eleven 
on oral antihyperglycemic agents only). Subject characteristics are described in table 1. BMI 
was > 25 kg/m² in all subjects, 14 subjects were overweight and 12 subjects were obese. 
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Table 1. Descriptive statistics and anthropometric measurements 
  All subjects n=26 Nordic n=16 South-Asian n=10 
  Mean SD Mean SD Mean SD 
Age 57 10 62 6 50 11 
n female (%)* 8 (31) 
 
5 (31) 
 
3 (30) 
 Height (cm) 170,8 8,4 172,5 8,8 168,0 7,4 
Weight (kg) 90,4 13,8 96,7 12,5 80,2 9,2 
BMI (kg/m²) 31,1 5,1 32,7 5,4 28,5 3,4 
Diabetes duration (years) 9 6 10 7 9 5 
SBP (mmHg) 131,8 15,4 133,3 15,6 129,4 15,6 
DBP (mmHg) 87,6 7,6 87,5 6,6 87,8 9,4 
Waist-to-hip ratio 1,04 0,06 1,04 0,07 1,03 0,06 
Fat (%) 34,5 7,5 35,8 8,4 32,3 5,6 
Lean body mass (kg) 55,7 8,3 58,4 8,4 51,4 6,2 
* Expressed as number and percent 
The Nordic subjects were older (p=0,01) and had higher body weight (p<0,01), BMI (p=0,02) 
and lean body mass (p=0,02) compared to South-Asians. Body height, known diabetes 
duration, blood pressure, waist-to-hip ratio and percent body fat did not differ significantly 
between the groups.  
 
Table 2. Diabetes measurements and lipids in Nordic and South-Asian subjects 
  All subjects n=24     Nordic n=14 South-Asian n=10 
  Median IQR Median IQR Median IQR 
Fasting P-glucose (mmol/l) 10,6 8,3-11,9 10,4 8,4-11,5 11,1 8,6-12,6 
HbA1c (%) 7,3 6,7-8,5 6,8 6,5-7,3 8,2 7,5-9,0 
P-Cholesterol (mmol/l) 4,1 3,2-4,9 4,2 3,3-5,3 4,0 3,2-4,8 
P-LDL (mmol/l)* 2,3 1,8-2,9 2,3 1,8-2,4 2,4 1,8-3,2 
P-HDL (mmol/l) 0,9 0,8-1,2 1,0 0,82-1,34 0,9 0,8-1,1 
P-Triglycerides (mmol/l) 1,3 0,9-1,9 1,5 1,1-1,9 1,1 0,9-1,7 
* Only available in 13 Nordic subjects 
There was no significant difference in fasting P-glucose, P-cholesterol, P-LDL, P-HDL or P-
triglycerides between Nordic and South-Asian. HbA1c was significantly higher in the South-
Asian group (p<0,01). Table 2 shows measures of glucose metabolism and lipids.  
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Table 3. Serum levels of 25-(OH) vitamin D, ionized calcium and PTH in Nordic and South-Asian 
subjects 
  All subjects n=26 Nordic n=16 South-Asian n=10 
  Median IQR Median IQR Median IQR 
S-25(OH) vitamin D (nmol/l) 39,0 29,0-44,8 40,0 28,0-45,5 35,0 29,8-41,5 
S-Ionized calcium (mmol/l)* 1,27 1,25-1,29 1,26 1,24-1,29 1,28 1,26-1,31 
P-PTH (pmol/l) 4,3 2,4-5,6 4,5 3,2-6,6 3,5 2,3-4,4 
* Data missing for one Nordic subject. 
All included subjects had vitamin D-deficiency – either moderate (S-25(OH) vitamin D 25-50 
nmol/l, n=22) or severe (S-25(OH) vitamin D < 25 nmol/l , n=5) at the screening visit. S-
ionized calcium was below 1,35 mmol/l in all subjects and S-PTH stretched from 1,2-11,4 
pmol/l at the screening visit. Se Table 3. 
 
Figure 2. Distribution of S-25(OH) vitamin D among Nordic and South-Asian subjects. 
 
No significant difference was found in S-25(OH) vitamin D, S-ionized calcium or S-PTH 
between the Nordic and South-Asian group. Distribution of S-25(OH) vitamin D is presented 
in a histogram (figure 2). S-25(OH) vitamin D was not significantly correlated with age, 
diabetes duration, blood pressure, fasting P-glucose, fasting S-insulin, HbA1c, 
anthropometric measures or P-lipids in any of the groups. 
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Serum levels of 25(OH) vitamin D did not show significant correlations to any of the insulin 
action measures performed (GIR: r=0,285 p=0,158, ISI: r=0,172 p=0,402, HOMAIR: r=-0,064 
p=0,756). Measures of insulin action separate for Nordic and South-Asian subjects are 
presented in table 4. Figure 3 shows a plot of the non-significant correlation between S-
25(OH) vitamin D and insulin sensitivity index (ISI) separate for Nordic and South Asian 
subjects.  
Table 4. Measures of insulin action in Nordic and South-Asian subjects 
  All subjects n=26 Nordic n=16 South-Asian n=10 
  Median IQR Median IQR Median IQR 
HOMAIR 1,7 1,1-3,0 2,1 1,1-3,4 1,6 1,0-2,0 
GIRffm (mmol/kg/min)* 4,79 3,61-6,41 4,68 3,08-6,06 5,88 4,14-6,84 
ISI* 4,97 2,43-6,09 4,22 0,94-5,43 5,25 4,60-6,77 
* Data missing for one Nordic and one South-Asian subject 
 
 
 
Figure 3. Correlation between 25-(OH) vitamin D and ISI separate for Nordic and South-Asian subjects 
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  GIRffm ISI HOMAIR WHR BMI 
GIRffm   
r= 0,923 
p<0,01 
r= -0,591 
p<0,01 
r= -0,395 
p=0,05 
r= -0,272 
p=0,179 
ISI 
r= 0,923 
p<0,01   
r= -0,582 
p<0,01 
r= -0,446 
p=0,02 
r= -0,300 
p=0,14 
HOMAIR 
r= -0,591 
p<0,01 
r= -0,582 
p<0,01   
r= 0,283 
p=0,161 
r= 0,389 
p=0,05 
WHR 
r= -0,395 
p=0,05 
r= -0,446 
p=0,02 
r= 0,283 
p=0,161   
r= 0,516 
p<0,01 
BMI 
r= -0,272 
p=0,179 
r= -0,300 
p=0,14 
r= 0,389 
p=0,05 
r= 0,516 
p<0,01   
 
Figure 4. Data correlating significantly with measures of insulin action. Significant correlations are 
marked out. 
 
Table 6. Characteristics of subjects based on S-25(OH)D (cutoff value: 40 nmol/l) 
  S-25(OH)D <40 nmol/l n=13 S-25(OH)D ≥ 40 nmol/l n=13 
n (%) 13 (50) 13 (50) 
sex (% female) 2 (15) 6 (46) 
Nordic (%) 7 (54) 9 (69) 
Age (years)* 56 ± 11 58 ± 10 
Weight (kg)* 88,8 ± 11,0 91,9 ± 16,5 
BMI (kg/m2)* 29,8 ± 4,2 32,3 ± 5,7 
Waist-to-hip ratio* 1,06 ± 0,07 1,01 ± 0,05 
Body fat (%)* 31,9 ± 7,1 37,0 ± 7,4 
Lean body mass (kg)* 57,2 ± 7,8 54,1 ± 8,8 
Diabetes duration (years)* 10 ± 6 9 ± 6 
HbA1c (%)**¤ 7,3 (6,7-8,0) 7,3 (6,7-8,5) 
*Data expressed as mean ± SD 
 ** Data expressed as median (IQR) 
 ¤ Data missing for two subjects in the S-25(OH)D ≥ 40 nmol/l group 
The waist-to-hip ratio was significantly higher in subjects with S-25(OH)D < 40 nmol/l 
(p=0,02), the other parameters did not differ. Table 6 demonstrates baseline characteristics 
for subjects divided according to S-25(OH) vitamin D with a cut off value of 40 nmol/l.  
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Table 7. Measures of insulin action in subjects above and below 40 nmol/l S-25(OH)D 
  S-25(OH)D <40 nmol/l n=13 S-25(OH)D ≥40 nmol/l n=13 
  Median IQR Median IQR 
HOMAIR 1,7 1,1-3,0 2,1 0,9-2,8 
GIRffm (mmol/kg/min)* 4,55 1,75-6,09 4,87 3,70-6,52 
ISI* 5,02 0,60-6,30 4,91 2,60-5,42 
* Data missing for one Nordic and one South Asian subject 
There was no significant difference in HOMAIR, GIRffm or ISI between those with S-25(OH) 
vitamin D <40 nmol/l and those with S-25(OH) vitamin D ≥40 nmol/l. See table 6. 
Diabetic late complications was found in 10 of the patients. 6 out of 13 in the S-25(OH) 
vitamin D <40-group had complications (three with retinopathy, one with neuro- and 
nephropathy, one with diabetes foot complications and one not specified) and 4 out of 13 in 
the S-25(OH) vitamin D ≥40-group (one with cardio-vascular, one with neuropathy and two 
not specified) (figure 5). Five with complications were Nordic and five were South-Asian. 
 
 
Figure 5. Prevalence of diabetic late complications according to S-25(OH) vitamin D status 
4 Discussion 
The main finding in the present study was that S-25(OH) vitamin D did not correlate 
significantly with any of the measurements of insulin action in the 26 included subjects of 
Nordic and South Asian ethnicity with type 2 diabetes. Furthermore, vitamin-D levels did not 
correlate to fasting S-glucose, fasting S-insulin or HbA1c. No significant difference in insulin 
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action between groups divided according to S-25(OH) vitamin D above or below 40 nmol/l 
was found. Our findings is in accordance with several previously reported studies (29;30).  
Although not significant, we observed correlation coefficients associating GIRffm, ISI and 
HOMAIR to S-25(OH) vitamin D in such a way that a larger study maybe would have found 
that insulin action is significantly correlated with higher levels of  S-25(OH) vitamin D,  as also 
have been reported in some previous studies (14;31;32). One study also reported improved 
insulin action after supplementation of vitamin D (33). We found some indications of a 
variable strength in relationship between insulin sensitivity and S-25(OH) vitamin D levels in 
Nordic versus South-Asian, although our groups were far too small to assess this in a proper 
way. The NHANES III reported different associations between S-25(OH) vitamin D and 
HOMAIR in different ethnic groups – a significant inverse correlation in Mexican American 
and inverse, but not significant in Non-Hispanic white but a slightly positive, non-significant 
correlation in Non-Hispanic black. They suggested a possibility of an ethnically related 
threshold effect of vitamin D with a decreased sensitivity of vitamin D among Non-Hispanic 
black (14).  
When subjects were divided into groups according to their S-25(OH) vitamin D level, only 
waist-to-hip ratio was found to be significantly different between the groups - with a higher 
waist-to-hip ratio in subjects below 40 nmol/l 25(OH) vitamin D. Furthermore, correlations 
between S-25(OH) vitamin D and waist-to-hip ratio were negative, but not significant, in all 
subjects together, in Nordic and South-Asian (p=0,06, 0,09 and 0,21 respectively). In contrast 
S-25(OH) vitamin D was positively correlated (not significant) with body fat percent and 
slightly positively correlated with BMI. This might indicate a specific relation between 
abdominal obesity and vitamin D deficiency, and not obesity per se, in accordance with one 
study finding a strong association between S-25(OH) vitamin D and abdominal obesity even 
after adjustment for obesity (15). Other studies have though reported a negative correlation 
between S-25(OH) vitamin D and BMI (29;32). In addition a significant inverse correlation 
between GIRffm, ISI and waist-to-hip ratio was found – showing a relation between insulin 
resistance and abdominal obesity.  
Many mechanisms have been proposed as a link between S-25(OH) vitamin D and diabetes. 
Bland et al. showed that pancreatic cells contain 25-hydroxyvitamin D3-1α-hydroxylase – the 
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enzyme converting vitamin D to its active form 1,25(OH)2D - and vitamin D receptors and 
that 1,25(OH)2D evoked a rise in [Ca
2+]i in insulin-secreting cells from mouse (11).  Maestro et 
al. demonstrated that the human insulin gene promoter has a vitamin D responsive element 
and that vitamin D increases the activity of the human insulin promoter (34). Pittas et al. 
suggested an indirect effect of vitamin D via regulation of extracellular calcium and calcium 
flux through β-cells, as insulin secretion is a calcium-dependent process. The same review 
also proposed that vitamin D, through modulation of the generation and effects of 
cytokines, may improve insulin sensitivity (35). One study, on the contrary, suggested that 
the association between S-25(OH) vitamin D and insulin resistance simply might be the result 
of increased body size (32).  
The strength of the present study was in particular that the euglycemic hyperinsulinemic 
glucose clamp method was used to assess the insulin sensitivity. This is considered to be the 
gold standard of measuring insulin sensitivity. In addition, the studied group of individuals 
was clearly defined by inclusion- and exclusion criteria. All subjects had vitamin D-deficiency 
and both Nordic and South-Asian were included. Only 26 subjects had so far been included 
and were available for this analyze of baseline data. Dividing those into subgroups according 
to S-25(OH) vitamin D level or ethnicity gave small numbers of subjects in each group. 
Particularly the South Asian group was small with only 10 subjects. Thus the statistical power 
to detect relationships was moderate. Also, as all the included subjects had moderate or 
severe vitamin D-deficiency at baseline the range of 25-(OH) vitamin D was fairly small which 
limits the power further. Furthermore, as this is a study of data at one point of time – the 
causative nature of the associations can not be established.  
5 Conclusion 
There was no significant difference in insulin sensitivity between groups divided according to 
levels of S-25(OH) vitamin D and no significant correlations between S-25(OH) vitamin D and 
HOMAIR, GIRffm or ISI were found. In the group with less than 40 nmol/l 25(OH) vitamin D, 
waist-to-hip ratio was significantly higher, which could advert abdominal obesity as a risk 
factor of vitamin D-deficiency or vice versa. As waist-to-hip ratio also was found to 
significantly correlate with insulin sensitivity expressed as GIRffm or ISI in all subjects 
collectively one could propose abdominal obesity to be a common risk factor of vitamin D-
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deficiency and insulin resistance.  A non-significant positive correlation between S-25(OH) 
vitamin D and insulin sensitivity in this study may indicate a possible relationship that needs 
to be studied in a larger population. 
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